[18F]SiTATE PET用于转移性肾上腺髓质及副神经节肿瘤的PRRT筛选与监测
本研究纳入5例转移性副神经节瘤(n=3)或嗜铬细胞瘤(n=2)患者,用[18F]SiTATE PET评估肽受体放射性核素治疗(PRRT)资格并监测疗效。基线所有患者病灶摄取高、Krenning评分3-4分,提示适合PRRT;PRRT完成后2.5个月,全部患者RECIST 1.1为稳定病、CgA下降或稳定,但3例总肿瘤体积(PET-based TTV)增加,显示异质性反应。结论认为[18F]SiTATE可有效显示肿瘤负荷并支持PRRT患者筛选与反应评估,但PET、CT与生化评估间的不一致机制尚不明确。
要点
- 基线[18F]SiTATE PET显示所有PPGL患者病灶高摄取,Krenning评分3-4分,支持PRRT资格。
- PRRT后2.5个月全部患者RECIST 1.1稳定病、CgA下降或稳定,但3例PET-based TTV增加。
- PET、CT与生化评估间反应不一致,机制待进一步研究。
核心结论
- 在转移性PPGL中,[18F]SiTATE可有效显示肿瘤负荷并支持PRRT患者选择与反应评估。
- PET-based、CT-based与生化评估间显示异质性反应,其机制尚不明确。
研究设计与样本
- 纳入5例转移性副神经节瘤(n=3)或嗜铬细胞瘤(n=2)患者。
- 用[18F]SiTATE PET结合Krenning评分和基线SUVmax评估PRRT资格。
- 用RECIST 1.1、PET-based总肿瘤体积(TTV)和嗜铬粒蛋白A(CgA)分析治疗反应。
主要发现
- 基线所有患者病灶摄取高,骨病灶最高(mean SUVmax 41.4 ± 87.3),Krenning评分3-4分。
- PRRT完成后2.5个月,全部患者RECIST 1.1为稳定病,CgA下降或稳定。
- 3例患者PET-based TTV增加,显示异质性反应。
关键数值与推荐
- PRRT资格评估采用Krenning评分和基线SUVmax。
- 治疗反应分析采用RECIST 1.1、PET-based TTV和CgA。
临床怎么用
- [18F]SiTATE PET可用于转移性PPGL的PRRT患者筛选。
- PRRT后需结合PET-based TTV、RECIST 1.1和CgA综合评估反应。
局限性
- 样本量仅5例,结论需更大样本验证。
- PET、CT与生化评估不一致的机制尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In somatostatin receptor (SSTR)-expressing tumors, theranostics with SSTR-directed imaging and therapy showed promising results regarding disease control. This study evaluated the use of PET imaging with [18F]SiTATE in pheochromocytoma and paraganglioma (PPGL) patients, focusing on eligibility for peptide radioreceptor therapy (PRRT) and therapy monitoring. METHODS: Five patients with metastatic paraganglioma (n = 3) or pheochromocytoma (n = 2) were included. Eligibility for PRRT was assessed by [18F]SiTATE applying the Krenning score and baseline SUVmax. Treatment response was analyzed by RECIST 1.1 criteria, total tumor volume (PET-based TTV), and Chromogranin A (CgA). RESULTS: At baseline, all patients showed high lesional uptake, with the highest in the bone (mean SUVmax 41.4 ± 87.3) and a high Krenning Score of 3-4, Suggestive for PRRT eligibility. At the follow up, 2.5 months after completion of PRRT, all patients presented with stable disease (RECIST 1.1) and decreasing or stable CgA levels, whereas TTV increased in three patients and thus showed heterogenous response. CONCLUSION: In metastatic PPGL, [18F]SiTATE effectively visualizes tumor burden and supports patient selection and response assessment for PRRT. Notably, the data revealed a heterogenous response across PET-based, CT-based, and biochemical assessments. The underlying mechanisms of these discrepancies remain unclear and warrant further investigation.
引用
- Siegmund SC, Holzgreve A, Schöll M, et al. [18F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paraganglia. Eur J Nucl Med Mol Imaging. 2025. PMID: 40970962. doi:10.1007/s00259-025-07550-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。